ABSTRACT
To achieve the goal of “eliminating viral hepatitis as a public health hazard by 2030”, extensive screening, active prevention, and antiviral therapy are currently recommended for chronic hepatitis B virus (HBV) infection; however, no consensus has been reached on whether to initiate antiviral therapy for patients in the immune-tolerant phase of chronic HBV infection. Some experts believe that patients in the immune-tolerant phase tend to have a stable liver immune microenvironment, with a low risk of disease progression and poor response to treatment, and thus it is not recommended to initiate antiviral therapy. However, various other studies have shown that patients in the immune-tolerant phase still have inflammatory damage in the liver, with a risk of disease progression and a high level of cost effectiveness, and therefore, some experts suggest that antiviral therapy should be actively initiated for patients in the immune-tolerant phase. This article performs a literature review of the definition of patients in the immune-tolerant phase of chronic HBV infection and the advantages and disadvantages of antiviral therapy and conducts a preliminary analysis based on previous studies, in order to accumulate the evidence for whether to initiate antiviral therapy in the immune-tolerant phase of chronic HBV infection and lay a foundation for standardized clinical diagnosis and treatment of patients in the immune-tolerant phase.
ABSTRACT
ObjectiveTo determine the scores of patients with a confirmed diagnosis of drug-induced liver injury (DILI) using Roussel Uclaf Causality Assessment Method (RUCAM), Maria & Victorino assessment scale, and Revised Electronic Causality Assessment Method (RECAM), to compare the accuracy of the three scales in diagnosis, and to investigate their clinical significance in the diagnosis of DILI. MethodsA total of 98 patients with a confirmed diagnosis of DILI who were hospitalized in Peking University First Hospital from January 2011 to December 2022 were enrolled, with liver biopsy results supporting DILI and a clear history of medication. Clinical data were collected from all subjects, and the above causality assessment scales were used for scoring. The chi-square test was used to analyze the diagnostic accuracy of the causality assessment scales, and the weighted kappa coefficient was used to analyze the consistency between the three scales. ResultsFor all patients with DILI enrolled, RECAM had the highest accuracy, with a significant difference compared with RUCAM (χ2=5.667,P=0.017). RUCAM and RECAM had moderate consistency in diagnosis (κw=0.469), while RECAM and Maria & Victorino scale had poor consistency (κw=0.156). For the patients with acute DILI, RECAM, RUCAM, and Maria & Victorino scales had a diagnostic inconsistency rate of 3.7%, 11.1%, and 42.6%, respectively; for the patients with hepatocellular type DILI, the three scales of a diagnostic inconsistency rate of 8.9%, 21.4%, and 62.5%, respectively; for the patients with cholestasis type or mixed type DILI, the three scales of a diagnostic inconsistency rate of 10.0%, 22.5%, and 47.5%, respectively. ConclusionThe use of RECAM and RUCAM scales in acute DILI can improve diagnostic rate, and for hepatocellular type DILI and DILI with the clinical manifestation of cholestasis (cholestasis type DILI and mixed type DILI), the use of RECAM and RUCAM scales can also improve diagnostic rate. The selection of causality assessment scales with a relatively high accuracy based on the course and clinical classification of the disease may help to further improve clinical diagnostic rate.
ABSTRACT
Objective To investigate the relationship between red blood cell distribution width (RDW) and prognosis in patients with multiple myeloma (MM).Methods The population that studied consisted of 27 patients with multiple myeloma and 30 healthy controls.The RDW was calculated according to the results of blood routine examination and compared between patients and healthy controls.Then,compared the difference between the two groups of RDW.MM patients were treated with international standard staging (ISS),and the differences of RDW in different stages were analyzed.ISS staging was used to draw the receiver operating curve (receiver operating characteristic curve,ROC curve),then take RDW14.65 % as the best cut-off point,the MM patients were divided into low RDW group (RDW=14.65 %) and high RDW group (RDW >14.65%).Overall survival (OS) condition were compared between the above two groups.The impacts of RDW on OS were analyzed by Kaplan-Meier and Log-rank test.Results The average RDW value in experimental and controlled were 15.60 % ± 2.35 % vs 12.72 % ±0.61 % separately (t=6.201,P<0.001),with statistical differences.The average RDW value in low ISS(Ⅰ + Ⅱ stage) and high ISS (Ⅲ stage) were 13.99 % ± 1.08% vs 16.55 %±2.39% separately (t=3.800,P=0.001).The median survival time of low RDW and high RDW group was 13 months and 8 months respectively,and the difference was statistically significant (x2=6.481,P =0.011).Conclusion RDW increased in patients with MM,the risk stratification higher prognosis is worse.
ABSTRACT
Objective To investigate the frequency of JAK2 V617F mutation and JAK2 V617F mutation allele burden in patients with essential thrombocythemia (ET), and explore the relationship between mutation and hematological parameters and coagulation function. Methods The clinical and laboratory parameters of 90 ET patients were analyzed. JAK2 V617F mutation was detected by AS-PCR and the mutation allele burden of JAK2 V617F was detected by qPCR. The correlation between mutation frequency and mutation burden of JAK2 V617F and blood laboratory parameters were investigated in ET. Results JAK2 V617F mutation was found in 50 patients (55.6 %). RBC [(4.67±0.89)×109/L vs (4.04±0.99)×109/L, P =0.003], WBC (11.64±5.20)×109/L vs (9.11±4.11)×109/L, P = 0.014], HCT (0.41±0.07) vs (0.36±0.07), P =0.005) in the JAK2 V617F mutated group were higher than those in the wild-type group. PT in mutated patients was longer than that in wild-type group [(13.18±1.63) s vs (12.02±1.24) s, P = 0.000]. The JAK2 V617F mutation allele burden was (29.91 ±18.63) %. No significant correlation was found between JAK2 V617F mutation allele burden and hematological parameters such as WBC, RBC and Plt (all P>0.05), but the JAK2 V617F mutation allele burden had a significant correlation with FDP (r = 0.456, P = 0.001). Conclusions JAK2 V617F mutation occurs in significant percentage patients with ET. Detection of JAK2 V617F mutation allele burden at diagnosis may play an important role in the early prevention of vascular events.